Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH): Two Products Receive Drug Registration Certificates

Stock News09-16

Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company recently received Drug Registration Certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved and issued by the National Medical Products Administration (NMPA).

According to relevant national policies, the company's Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved for production as Class 3 chemical drugs, are deemed equivalent to passing consistency evaluation.

The receipt of Drug Registration Certificates from the NMPA for these two products further enriches the company's product portfolio and helps enhance the market competitiveness of the company's products, having a positive impact on the company's business development.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1105487824?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-16 17:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1105487824","market":"fut","top_or_hot":-1,"title":"Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH): Two Products Receive Drug Registration Certificates","media":"Stock News","content":"<p>Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company recently received Drug Registration Certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved and issued by the National Medical Products Administration (NMPA).</p>\n<p>According to relevant national policies, the company's Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved for production as Class 3 chemical drugs, are deemed equivalent to passing consistency evaluation.</p>\n<p>The receipt of Drug Registration Certificates from the NMPA for these two products further enriches the company's product portfolio and helps enhance the market competitiveness of the company's products, having a positive impact on the company's business development.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH): Two Products Receive Drug Registration Certificates</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH): Two Products Receive Drug Registration Certificates\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-09-16 17:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company recently received Drug Registration Certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved and issued by the National Medical Products Administration (NMPA).</p>\n<p>According to relevant national policies, the company's Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved for production as Class 3 chemical drugs, are deemed equivalent to passing consistency evaluation.</p>\n<p>The receipt of Drug Registration Certificates from the NMPA for these two products further enriches the company's product portfolio and helps enhance the market competitiveness of the company's products, having a positive impact on the company's business development.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"","article_id":"1105487824","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1105487824","pubTimestamp":1758014323,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company recently received Drug Registration Certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600521":"华海药业","BK0028":"国家队","BK0239":"医药制造","BK0185":"二线龙头","BK0201":"可转债","BK0070":"员工持股","BK0188":"融资融券","BK0012":"证金概念"},"translate_title":"浙江华海药业股份有限公司。（600521.SH）：两款产品获药品注册证","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600521":1},"content_text":"Zhejiang Huahai Pharmaceutical Co.,Ltd. (600521.SH) announced that the company recently received Drug Registration Certificates for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved and issued by the National Medical Products Administration (NMPA).\nAccording to relevant national policies, the company's Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) and Roxatidine Acetate Hydrochloride for Injection, approved for production as Class 3 chemical drugs, are deemed equivalent to passing consistency evaluation.\nThe receipt of Drug Registration Certificates from the NMPA for these two products further enriches the company's product portfolio and helps enhance the market competitiveness of the company's products, having a positive impact on the company's business development.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1105487824","isCrawlerRequest":true}